Quantcast
Last updated on April 24, 2014 at 11:28 EDT

Latest Spasmodic torticollis Stories

2011-10-25 07:11:00

GREENSBORO, N.C., Oct. 25, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, today announced that data from studies evaluating the dosing and adverse event profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, in the treatment of blepharospasm (eyelid spasms) will be presented at the 115th Annual Meeting of the American Association of Ophthalmology (AAO) in Orlando, Fla. These data include an extension of the Phase III,...

2011-10-21 08:01:00

FRANKFURT AM MAIN, Germany, October 21, 2011 /PRNewswire/ -- At the 5th International Dystonia Symposium (IDS) in Barcelona, Spain (20-22 October 2011), Merz Pharmaceuticals presented important clinical data concerning the long-term, sustained efficacy and safety of XEOMIN(R) for the treatment of patients with dystonia. Dystonia is a particularly debilitating condition where involuntary muscle contractions can cause abnormal twisting, postures or movements, and is the...

health-082511-004
2011-08-25 09:27:14

  The US Food and Drug Administration (FDA) has given approval for Allergan, the maker of Botox, to market the drug to treat a specific kind of overactive bladder condition, Reuters is reporting. After receiving similar approval in Europe earlier this month, US regulators are allowing Botox to be injected into the bladder to treat those who lose bladder control because of damage to the nervous system through conditions such as multiple sclerosis or spinal cord injury. Botox´...

2011-06-08 12:30:00

FRANKFURT, Germany, June 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that new data on Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the Movement Disorder Society's (MDS) 15th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada. The studies found that repeated injections of XEOMIN were safe and effective in the treatment of blepharospasm and...

2011-05-07 00:00:29

Noel Valero, founder of the American Dystonia Society (ADS), has carved out a section of its website for its members to ask questions of Social Security disability representative Frederick Johnson. The section has been dubbed "Ask Fred About SSDI." Pooler, GA (PRWEB) May 06, 2011 Frederick Johnson, a Social Security disability representative and president of Disability Income Associates, LLC, with 21 years of experience in helping over 1,000 patients get Social Security disability...

2011-04-14 07:11:00

GREENSBORO, N.C., April 14, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, maker of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign. With the help of patient advocates, "Make Your Mark" celebrates the inspirational stories of people living with blepharospasm or cervical dystonia (CD), also known as spasmodic torticollis, and aims to raise awareness of these often...

2011-04-12 08:00:00

FRANKFURT, Germany, April 12, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that results from sub-group analyses of a prospective, repeated dose, double-blind study evaluating the long-term safety and efficacy of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii, U.S. The data show that repeated injections...

2011-03-30 07:11:00

GREENSBORO, N.C., March 30, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for Xeomin® (incobotulinumtoxinA). Merz expects that this unique billing code, which will become effective on April 1, 2011, will help simplify the billing and reimbursement process for prescribers of XEOMIN. The U.S. Food and Drug...

2011-03-09 13:01:34

Implanting electrodes into a pea-sized part of the brain can dramatically improve life for people with severe cervical dystonia "“ a rare but extremely debilitating condition that causes painful, twisting neck muscle spasms "“ according to the results of a pilot study led by Jill Ostrem, MD and Philip Starr, MD PhD at the University of California, San Francisco. Today, people with cervical dystonia can be treated with medications or injections of botulinum toxin (e.g.,...

2011-03-08 07:11:00

GREENSBORO, N.C., March 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced the launch of two programs to provide financial assistance to patients for their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum toxin type A free from accessory proteins that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum...